DSpace Repository

Impact of Emicizumab on annualized bleeding rates in persons with haemophilia A in Western Kenya

Impact of Emicizumab on annualized bleeding rates in persons with haemophilia A in Western Kenya

Kilach, C.; Njuguna, F.; Greist, A.; Njuguna, C.; Midiwo, Nancy; Oburah, E.; Aliwa, E.; Korir, R.; Bor, C.
URI: https://www.postersessiononline.eu/173580348_eu/congresos/WFH2022/aula/-PP_64_WFH2022.pdf
http://ir.mu.ac.ke:8080/jspui/handle/123456789/10498
Date: 2022

Abstract:

Prophylactic treatment for Persons with Hemophilia (PWH) still remains largely inaccessible in Kenya. Donation of Emicizumab for PWH A through the World Federation of Hemophilia (WFH) Humanitarian Aid Programme in March 2021, started the first sustainable prophylaxis programme in Kenya.

Show full item record

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account